Profit Warnings & Insulin Pricing

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics feel particularly urgent given the shifting sands in US healthcare economics.

MarcusSame here. We're looking at HCA's profit warning and its implications for hospital access — that's a system-wide signal. Then the subcutaneous Leqembi approval and what it means for HEOR evidence generation. Plus the FTC settlement with CVS Caremark over insulin pricing, which could reconfigure pharmacy benefit dynamics. And finally, ICER's expansion of scientific advice services.

SaraThat second one about Leqembi catches my attention — the evidence requirements for Alzheimer's treatments are becoming increasingly complex, and I wonder how payers will balance that against budget constraints.

MarcusExactly. Let's get into it.

MarcusStarting with HCA's profit warning. The largest US hospital operator cited 'unprecedented' financial pressures, with operating margins under severe strain. This isn't just a corporate issue; it signals broader system stress that could cascade to drug access decisions. When hospital systems struggle, formulary negotiations get tougher, and patient access to innovative therapies becomes vulnerable.

SaraThat's one read — but I'd frame it slightly differently. The part that gives me pause is how this interacts with Medicare Advantage star ratings. If hospitals cut costs to protect margins, they might deprioritize high-cost drugs, creating a de facto access barrier that formal HTA doesn't capture. We're seeing this play out in oncology already.

MarcusThat's fair, though I think the innovation side would argue that hospital profitability is directly tied to their ability to invest in advanced care infrastructure that supports new treatments. The system can't sustain both innovation and access without financial stability.

SaraBut the data shows margins compressing across the board, not just for high-cost services. The question is whether this is a cyclical blip or structural decline. If it's structural, we may need new payment models that decouple hospital profitability from drug utilization.

MarcusWhat strikes me here is the timing. Coming post-IRA implementation, this could reflect early-stage CMS payment shifts. HCA's scale makes this a bellwether — we should watch for similar signals from other large systems.

SaraAbsolutely. And from the payer side, this reinforces the need for real-world evidence that demonstrates total system value, not just drug costs. If hospital readmissions go up because of restricted access, the budget impact multiplies.

MarcusShifting to subcutaneous Leqembi. The FDA approval for this administration route is significant — it transforms the patient experience and could expand treatment eligibility. But from an evidence perspective, it raises questions about whether new data is needed for this formulation or if it's a straightforward extrapolation from the intravenous version.

SaraThat's the key question. IHC has already signaled that real-world evidence on adherence and persistence will be critical here. If subQ improves tolerability, we might see better outcomes that weren't captured in pivotal trials. But generating that evidence takes time, and payers will need interim guidance.

MarcusExactly. And what's interesting is how this connects to the broader Alzheimer's treatment landscape. With multiple disease-modifying therapies emerging, HEOR teams will need to develop comparative effectiveness frameworks that account for administration differences. This isn't just about efficacy anymore.

SaraI'd push back slightly on that. While administration matters, the fundamental cost-effectiveness question remains unchanged: are these therapies delivering meaningful health gains at a system-sustainable price? The subQ route might reduce caregiver burden, but quantifying that in QALYs is methodologically challenging.

MarcusThat's a valid methodological point. But from the patient perspective, reducing treatment burden is a real-world outcome that impacts quality of life. The challenge is translating that into evidence that payers recognize. We might need new PRO frameworks specifically designed for administration route comparisons.

SaraWhich brings us back to the budget impact. Even if subQ improves outcomes, if the price remains unchanged, the cost per QALY could worsen. Payers will need reassurance that any additional benefit justifies the cost, especially given the current fiscal environment for Medicare.

MarcusNow the FTC settlement with CVS Caremark over insulin pricing. The FTC alleged that CVS improperly steered patients to higher-cost insulin products, violating antitrust laws. The settlement includes $77 million in consumer redress and requires changes to pharmacy benefit design. This isn't just about insulin; it's about the opaque mechanics of pharmacy benefit manager influence on drug selection.

SaraThat's one interpretation — but I'd frame it as a significant intervention in the insulin market dynamics. The FTC's focus on steering practices suggests they're viewing PBMs as gatekeepers with systemic influence. If this leads to more transparent formulary decisions, it could create precedents for other high-cost drugs.

MarcusWhat strikes me here is the potential for unintended consequences. If PBMs are restricted in their ability to negotiate rebates, manufacturers might raise list prices to compensate, ultimately increasing net costs. The system needs to distinguish between legitimate rebates and anti-competitive steering.

SaraThe part that gives me pause is how this interacts with the IRA insulin cap. If PBMs can no longer steer patients to higher-cost versions, the $35 monthly cap might become more effective. But we need to see if the settlement actually changes patient behavior or just shifts financial flows.

MarcusAnd from the manufacturer perspective, this could accelerate value-based contracting models where rebates are tied to real-world outcomes rather than formulary placement. The FTC action might push the industry toward more transparent value demonstrations.

SaraWhich brings us back to access. If the settlement reduces out-of-pocket costs for insulin patients, that's a win. But the broader implication is about market power — if PBMs lose their leverage, will they compensate by restricting access to other innovative therapies? That's the tension we need to monitor.

MarcusFinally, ICER's expansion of scientific advice services. They're increasing capacity and adding new advisory modules, including early evidence generation support and health technology assessment preparation. This reflects growing demand for pre-submission guidance from manufacturers navigating complex evidence landscapes.

SaraThat's a significant development — but I wonder if this is meeting payer needs or manufacturer demands. From the HTA perspective, we need scientific advice that aligns with real-world decision-making frameworks, not just regulatory pathways. The question is whether ICER's expansion translates to more actionable guidance for payers.

MarcusExactly. And what's interesting is how this connects to the EU JCA experience. ICER's expansion might signal a move toward more structured, collaborative evidence development. If manufacturers engage earlier with evidence strategy, it could reduce the risk of HTA rejections later. That's a win for both sides.

SaraI'd frame it slightly differently. The expansion is a response to the increasing complexity of evidence requirements, but it doesn't address the fundamental challenge of aligning HEOR endpoints with payer priorities. If ICER's advice focuses on regulatory acceptance rather than value demonstration, we might not see improved access outcomes.

MarcusThat's a fair point. But the expansion includes specific modules on health economic modeling and real-world evidence design, which directly address payer concerns. The key will be whether ICER can maintain its independence while offering more comprehensive services. If they become too closely aligned with manufacturer needs, their credibility could suffer.

SaraWhich brings us to the sustainability question. If scientific advice becomes a standard part of development, who bears the cost? Manufacturers will pass those costs through to pricing, and payers will need to justify them in budget impact analyses. The system needs to demonstrate that early advice improves overall efficiency.

SaraA lot to think about today. I'll be watching how HCA's financial pressures translate to formulary decisions, especially for high-cost hospital-administered drugs. The Leqembi subQ approval will test whether administration route differences can be meaningfully valued in HTA.

MarcusSame — and for me the thread running through today is the growing tension between system sustainability and innovation. Whether it's hospital finances, insulin pricing, or evidence generation, the industry needs to demonstrate total system value, not just product benefits.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.